دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Dermatology has no walls: a perspective on international exchange
A.S. Murthy,M.-M. Chren,K. Linos,E. Linos
doi : 10.1111/bjd.19931
British Journal of DermatologyVolume 184, Issue 5 p. 787-789
Evidence for efficacy of home-based narrowband ultraviolet B therapy
A. Wolkerstorfer
doi : 10.1111/bjd.19749
British Journal of DermatologyVolume 184, Issue 5 p. 790-790
Phototherapy with or without photosensitizers has been used for thousands of years for the treatment of various skin disorders. In addition to controlling the inflammatory component, it also stimulates the proliferation and migration of melanocytes.1 Currently, in vitiligo, narrowband 311-nm ultraviolet B (NB-UVB) therapy is the first choice for treating widespread and active disease.2, 3 The introduction of this treatment for vitiligo by Westerhof et al. in 1997 was a milestone in the field.4 However, unlike eczema and psoriasis where excellent outcomes (90% reductions in Psoriasis Area and Severity Index and Eczema Area and Severity Index, respectively) can be achieved within 8 to 12 weeks, outcomes in vitiligo are far less favourable, and a 90% improvement in Vitiligo Area Scoring Index is still far away from clinical practice. Therefore, NB-UVB is often combined with topical corticosteroids to enhance efficacy. Nevertheless, the duration of treatment is typically 9–12 months to reach approximately 40–50% repigmentation.
Secukinumab 2-weekly vs. 4-weekly dosing in plaque-type psoriasis
T.-F. Tsai
doi : 10.1111/bjd.19570
British Journal of DermatologyVolume 184, Issue 5 p. 791-792
Long-term safety of dupilumab in children
C. Sibbald
doi : 10.1111/bjd.19613
British Journal of DermatologyVolume 184, Issue 5 p. 792-793
Using electronic health records to examine links between atopic dermatitis and obesity
J.A. Lucas
doi : 10.1111/bjd.19758
British Journal of DermatologyVolume 184, Issue 5 p. 793-793
The skin as a target for SARS-CoV-2 infection: exploiting the web for suitable data
L. Naldi
doi : 10.1111/bjd.19877
British Journal of DermatologyVolume 184, Issue 5 p. 793-794
In this issue of the BJD, Visconti et al. present the results of a mobile app survey of symptoms related with SARS-CoV-2 infection, combined with an independent web-based data collection of skin manifestations and clinical pictures in patients presumably infected by the virus, for expert review.1 The study documents that self-reported transient skin rashes, classifiable a posteriori by experts as papular rashes, urticaria or acral lesions, are more frequent in people testing positive on a swab for SARS-CoV-2 than in people testing negative, and in untested users with a history of at least one of the three main symptoms of COVID-19 (i.e. fever, persistent cough and/or anosmia) than in people lacking any of these symptoms. Notably, in about 38% of people testing positive for SARS-CoV-2 (either by swab or by antibodies) and reporting skin manifestations, cutaneous symptoms either appeared before any other symptoms or were the only clinical manifestation. Rather surprisingly, the association of a positive SARS-CoV-2 test was stronger for any skin rash than for fever, an established symptom of COVID-19, the odds ratios for the associations being 1·67 and 1·48, respectively.
Patient-oriented outcomes for atopic dermatitis
T. Vazquez,J.S.S. Concha,V.P. Werth
doi : 10.1111/bjd.19614
British Journal of DermatologyVolume 184, Issue 5 p. 794-795
A child’s experience of itch: the first step towards patient-centred measures
C.K. Zigler,A. Roberts
doi : 10.1111/bjd.19678
British Journal of DermatologyVolume 184, Issue 5 p. 795-796
A growing family of outcome measurement proposals for hidradenitis suppurativa
L. Emtestam,J. Lapins,K. Sartorius
doi : 10.1111/bjd.19712
British Journal of DermatologyVolume 184, Issue 5 p. 796-798
Hidradenitis suppurativa (HS) seems to originate within the hair follicle infundibulum. Occlusion is followed by inflammation and development of the disease. For treatment, surgery is the gold standard,1 but it is not always practical, and in randomized controlled trials (RCTs), an anti-tumour necrosis factor-? agent was promising for HS.2 Genetics and other factors, such as smoking, microbes and adiposity, contribute to the disease phenotype, which includes boils, noduli, scars, secreting or nonsecreting fistulae (‘tunnels’), and inflammation mainly of inverse areas.3
Identification of keratinocyte subpopulations in transcriptome to evaluate drug effects in atopic dermatitis
T. Miyano,R.J. Tanaka
doi : 10.1111/bjd.19615
British Journal of DermatologyVolume 184, Issue 5 p. 798-799
no abstract
Linked in: the extracellular matrix network in tumour dissemination
V. Leb-Reichl,C. Guttmann-Gruber,J. Pi?on Hofbauer
doi : 10.1111/bjd.19617
British Journal of DermatologyVolume 184, Issue 5 p. 799-799
The focus of cancer research initially lay on individual tumour cells and uncovering the cell-intrinsic hallmarks and deregulated pathways that distinguished these from their normal counterparts. However, today, cancers are investigated as entities, and include the nonmalignant cells and noncellular components of the tumour microenvironment that enable and perpetuate this corrupted cell behaviour. The extracellular matrix (ECM) comprises up to 60% of a tumour’s mass.1 This heterogeneous, but well-orchestrated, three-dimensional meshwork of proteoglycans and insoluble fibrillar proteins, such as collagens, elastins, fibronectins and laminins, imparts important biophysical and biochemical properties to tissue.2 Far from being an inert intercellular filler, the ECM is a dynamic structure that is constantly being remodelled and is a key regulator of many crucial cellular processes. The ECM proteome, also known as the matrisome, consists of approximately 300 core and 700 associated proteins.3 As these are interconnected via the same network, alterations in single components tend to have serious knock-on effects. Unsurprisingly, matrisome composition is altered in cancer, with significant downstream consequences for tumour progression.
Translational genetics: a challenging but important path
S.J. Brown
doi : 10.1111/bjd.19618
British Journal of DermatologyVolume 184, Issue 5 p. 800-801
Hair disorders can be difficult to address in clinic, not least because our current understanding of molecular mechanisms and targeted therapies remains limited. Loose anagen syndrome (OMIM 600628) is reportedly rare, although cases may remain undiagnosed because the condition is usually self-limiting. A genetic predisposition with dominant inheritance has been observed1 and the shed hairs may be thinner and longitudinally grooved.2 It has therefore been suggested that variation in KRT75 (OMIM *609025), encoding a keratin of the inner root sheath companion layer, may account for loose anagen and unruly hair.3
Exploring the human hair follicle microbiome*
M.B. Lousada,T. Lachnit,J. Edelkamp,T. Rouillé,D. Ajdic,Y. Uchida,A. Di Nardo,T.C.G. Bosch,R. Paus
doi : 10.1111/bjd.19461
British Journal of DermatologyVolume 184, Issue 5 p. 802-815
Human hair follicles (HFs) carry complex microbial communities that differ from the skin surface microbiota. This likely reflects that the HF epithelium differs from the epidermal barrier in that it provides a moist, less acidic, and relatively ultraviolet light-protected environment, part of which is immune-privileged, thus facilitating microbial survival. Here we review the current understanding of the human HF microbiome and its potential physiological and pathological functions, including in folliculitis, acne vulgaris, hidradenitis suppurativa, alopecia areata and cicatricial alopecias. While reviewing the main human HF bacteria (such as Propionibacteria, Corynebacteria, Staphylococci and Streptococci), viruses, fungi and parasites as human HF microbiome constituents, we advocate a broad view of the HF as an integral part of the human holobiont. Specifically, we explore how the human HF may manage its microbiome via the regulated production of antimicrobial peptides (such as cathelicidin, psoriasin, RNAse7 and dermcidin) by HF keratinocytes, how the microbiome may impact on cytokine and chemokine release from the HF, and examine hair growth-modulatory effects of antibiotics, and ask whether the microbiome affects hair growth in turn. We highlight major open questions and potential novel approaches to the management of hair diseases by targeting the HF microbiome.
Prevalence, pathophysiology and management of itch in epidermolysis bullosa*
M. Papanikolaou,A. Onoufriadis,J.E. Mellerio,L.A. Nattkemper,G. Yosipovitch,M. Steinhoff,J.A. McGrath
doi : 10.1111/bjd.19496
British Journal of DermatologyVolume 184, Issue 5 p. 816-825
Epidermolysis bullosa (EB) is a highly diverse group of inherited skin disorders, resulting from mutations in genes encoding proteins of the dermoepidermal junction. Itch (pruritus) is one of the most common symptoms across all EB subtypes. It occurs in blistered or wounded sites, or manifests as a generalized phenomenon, thereby affecting both intact skin and healing wounds. The mechanism of pruritus in EB is unclear. It is likely that skin inflammation secondary to barrier disruption, wound healing cascades and dysregulated activation of epidermal sensory nerve endings are all involved in its pathophysiology on the molecular and cellular level. Understanding these mechanisms in depth is crucial in developing optimized treatments for people with EB and improving quality of life. This review summarizes current evidence on the prevalence, mechanisms and management of itch in EB.
‘Ruxolitinib cream for the treatment of vitiligo: a randomised, controlled, phase 2 trial': a critical appraisal
C. Cotter,J. Ferguson
doi : 10.1111/bjd.19674
British Journal of DermatologyVolume 184, Issue 5 p. 826-827
Randomized controlled trial of topical corticosteroid and home-based narrowband ultraviolet B for active and limited vitiligo: results of the HI-Light Vitiligo Trial*
K.S. Thomas,J.M. Batchelor,P. Akram,J.R. Chalmers,R.H. Haines,G.D. Meakin,L. Duley,J.C. Ravenscroft,A. Rogers,T.H. Sach,M. Santer,W. Tan,J. White,M.E. Whitton,H.C. Williams,S.T. Cheung,H. Hamad,A. Wright,J.R. Ingram,N.J. Levell,J.M.R. Goulding,A. Makrygeorgou,A. Bewley,M. Ogboli,J. Stainforth,A. Ferguson,B. Laguda,S. Wahie,R. Ellis,J. Azad,A. Rajasekaran,V. Eleftheriadou,A.A. Montgomery,on behalf of the UK Dermatology Clinical Trials Network’s HI-Light Vitiligo Trial Team
doi : 10.1111/bjd.19592
British Journal of DermatologyVolume 184, Issue 5 p. 828-839
To determine the effectiveness of (i) handheld narrowband UVB (NB-UVB) and (ii) a combination of potent topical corticosteroid (TCS) and NB-UVB, compared with TCS alone, for localized vitiligo.
An economic evaluation of the randomized controlled trial of topical corticosteroid and home-based narrowband ultraviolet B for active and limited vitiligo (the HI-Light Vitiligo Trial)*
T.H. Sach,K.S. Thomas,J.M. Batchelor,A. Perways,J.R. Chalmers,R.H. Haines,G.D. Meakin,L. Duley,J.C. Ravenscroft,A. Rogers,M. Santer,W. Tan,J. White,M.E. Whitton,H.C. Williams,S.T. Cheung,H. Hamad,A. Wright,J.R. Ingram,N. Levell,J.M.R. Goulding,A. Makrygeorgou,A. Bewley,M. Ogboli,J. Stainforth,A. Ferguson,B. Laguda,S. Wahie,R. Ellis,J. Azad,A. Rajasekaran,V. Eleftheriadou,A.A. Montgomery,the UK Dermatology Clinical Trials Network’s HI-Light Vitiligo Trial Team
doi : 10.1111/bjd.19554
British Journal of DermatologyVolume 184, Issue 5 p. 840-848
To determine the cost-effectiveness of (i) handheld narrowband ultraviolet B (NB-UVB) and (ii) a combination of topical corticosteroid (TCS) and NB-UVB compared with TCS alone for localized vitiligo.
Secukinumab 2-weekly vs. 4-weekly dosing in patients with plaque-type psoriasis: results from the randomized GAIN study*
K. Reich,A. K?rber,U. Mrowietz,M. Sticherling,C. Sieder,J. Früh,T. Bachhuber
doi : 10.1111/bjd.19398
British Journal of DermatologyVolume 184, Issue 5 p. 849-856
Secukinumab is a fully human monoclonal antibody that selectively neutralizes interleukin-17A and shows long-lasting efficacy and safety in plaque psoriasis. More evidence is required to optimize secukinumab dosing according to clinical response.
Dupilumab provides favourable long-term safety and efficacy in children aged ? 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension study
M.J. Cork,D. Thaçi,L.F. Eichenfield,P.D. Arkwright,X. Sun,Z. Chen,B. Akinlade,S. Boklage,I. Guillemin,M.P. Kosloski,M.A. Kamal,J.T. O’Malley,N. Patel,N.M.H. Graham,A. Bansal
doi : 10.1111/bjd.19460
British Journal of DermatologyVolume 184, Issue 5 p. 857-870
Children aged ? 6 to < 12 years with severe atopic dermatitis (AD) have limited treatment options. In a 16-week, randomized, placebo-controlled, phase III trial in children, dupilumab, a monoclonal antibody inhibiting interleukin (IL)-4/IL-13 signalling, significantly improved signs and symptoms with acceptable safety; longer-term safety and efficacy data are lacking.
Atopic eczema and obesity: a population-based study*
A. Ascott,K.E. Mansfield,Y. Schonmann,A. Mulick,K. Abuabara,A. Roberts,L. Smeeth,S.M. Langan
doi : 10.1111/bjd.19597
British Journal of DermatologyVolume 184, Issue 5 p. 871-879
Atopic eczema is a common chronic inflammatory skin disease. Research suggests an association between atopic eczema and obesity, with inconsistent evidence from European populations.
Diagnostic value of cutaneous manifestation of SARS-CoV-2 infection*
A. Visconti,V. Bataille,N. Rossi,J. Kluk,R. Murphy,S. Puig,R. Nambi,R. C. E. Bowyer,B. Murray,A. Bournot,J. Wolf,S. Ourselin,C. J. Steves,T. D. Spector,M. Falchi
doi : 10.1111/bjd.19807
British Journal of DermatologyVolume 184, Issue 5 p. 880-887
One of the challenging aspects of SARS-CoV-2 infection is its diverse multisystemic disease presentation.
What are the best endpoints for Eczema Area and Severity Index and Scoring Atopic Dermatitis in clinical practice? A prospective observational study*
J.I. Silverberg,D. Lei,M. Yousaf,S.R. Janmohamed,P.P. Vakharia,R. Chopra,R. Chavda,S. Gabriel,K.R. Patel,V. Singam,R. Kantor,D.Y. Hsu
doi : 10.1111/bjd.19457
British Journal of DermatologyVolume 184, Issue 5 p. 888-895
Multiple strategies have been used to evaluate the minimal important change (MIC) of the Eczema Area and Severity Index (EASI) and Scoring Atopic Dermatitis (SCORAD). The meaningfulness of these MICs is not well established across all severities of atopic dermatitis (AD).
Characteristics and impacts of itch in children with inflammatory skin disorders*
M.M. Fang,C.J. Nowinski,J. Lai,S. Shaunfield,J.I. Silverberg,S.M. Rangel,D. Cella,A.S. Paller
doi : 10.1111/bjd.19541
British Journal of DermatologyVolume 184, Issue 5 p. 896-904
Itch is a cardinal feature of paediatric disorders and can impair quality of life. However, few studies have addressed symptoms and impacts of itch in paediatric patients.
Hidradenitis Suppurativa Area and Severity Index Revised (HASI-R): psychometric property assessment*
N. Goldfarb,M. A. Lowes,M. Butt,T. King,A. Alavi,J. S. Kirby
doi : 10.1111/bjd.19565
British Journal of DermatologyVolume184, Issue5,May 2021,Pages 905-912
Validated, reliable, globally accepted outcome measurement instruments for hidradenitis suppurativa (HS) are needed. Current tools to measure the physical signs domain for HS rely on lesion counts, which are time-consuming and unreliable.
Machine learning applied to atopic dermatitis transcriptome reveals distinct therapy-dependent modification of the keratinocyte immunophenotype*
K. Clayton,A. Vallejo,S. Sirvent,J. Davies,G. Porter,I.C. Reading,F. Lim,M.R. Ardern-Jones,M.E. Polak
doi : 10.1111/bjd.19431
British Journal of DermatologyVolume 184, Issue 5 p. 913-922
Atopic dermatitis (AD) arises from a complex interaction between an impaired epidermal barrier, environmental exposures, and the infiltration of T helper (Th)1/Th2/Th17/Th22 T cells. Transcriptomic analysis has advanced our understanding of gene expression in cells and tissues. However, molecular quantitation of cytokine transcripts does not predict the importance of a specific pathway in AD or cellular responses to different inflammatory stimuli.
Loss of the laminin subunit alpha-3 induces cell invasion and macrophage infiltration in cutaneous squamous cell carcinoma*
M.P. Caley,V.L. Martins,K. Moore,M. Lashari,L. Nissinen,V.-M. K?h?ri,S. Alexander,E. Jones,C.A. Harwood,J. Jones,M. Donaldson,J.F. Marshall,E.A. O’Toole
doi : 10.1111/bjd.19471
British Journal of DermatologyVolume 184, Issue 5 p. 923-934
Cutaneous squamous cell carcinoma (cSCC) is a common cancer that invades the dermis through the basement membrane. The role of the basement membrane in poorly differentiated cSCC is not well understood.
Autosomal recessive hypotrichosis with loose anagen hairs associated with TKFC mutations*
A. Onoufriadis,A. Cabezas,J.C.F. Ng,J. Canales,M.J. Costas,J.M. Ribeiro,J.R. Rodrigues,M.A. McAleer,L. Castelo-Soccio,M.A. Simpson,F. Fraternali,A.D. Irvine,J.C. Cameselle,J.A. McGrath
doi : 10.1111/bjd.19481
British Journal of DermatologyVolume 184, Issue 5 p. 935-943
Loose anagen hair is a rare form of impaired hair anchorage in which anagen hairs that lack inner and outer root sheaths can be gently and painlessly plucked from the scalp. This condition usually occurs in children and is often self-limiting. A genetic basis for the disorder has been suggested but not proven. A better understanding the aetiology of loose anagen hair may improve prevention and treatment strategies.
Validation of a clinicopathological and gene expression profile model for sentinel lymph node metastasis in primary cutaneous melanoma*
E.E.A.P. Mulder,J.T. Dwarkasing,D. Tempel,A. van der Spek,L. Bosman,D. Verver,A.L. Mooyaart,A.A.M. van der Veldt,C. Verhoef,T.E.C. Nijsten,D.J. Grunhagen,L.M. Hollestein
doi : 10.1111/bjd.19499
British Journal of DermatologyVolume 184, Issue 5 p. 944-951
The Clinicopathological and Gene Expression Profile (CP-GEP) model was developed to accurately identify patients with T1–T3 primary cutaneous melanoma at low risk for nodal metastasis.
Environmental sustainability in dermatological surgery
C.L. Chaplin,A.G.H. Wernham,D. Veitch
doi : 10.1111/bjd.19668
British Journal of DermatologyVolume 184, Issue 5 p. 952-953
Quality assurance and characterization of narrowband ultraviolet B devices for use at home: lessons from the HI-Light Vitiligo Trial
A. Rogers,P. Akram,J.M. Batchelor,J. Crutchley,M. Grocki,R.H. Haines,G. Meakin,K. O’Dowd,J. Ravenscroft,K.S. Thomas
doi : 10.1111/bjd.19630
British Journal of DermatologyVolume 184, Issue 5 p. 954-955
Assessing the validity, responsiveness and reliability of the Recap measure of eczema control
A. Bhanot,T.J. Peters,M.J. Ridd
doi : 10.1111/bjd.19709
British Journal of DermatologyVolume 184, Issue 5 p. 955-957
An independent external validation of melanoma risk prediction models using the Australian Melanoma Family Study
K. Vuong,B.K. Armstrong,D. Espinoza,J.L. Hopper,J.F. Aitken,G.G. Giles,H. Schmid,G.J. Mann,A.E. Cust,K. McGeechan
doi : 10.1111/bjd.19706
British Journal of DermatologyVolume 184, Issue 5 p. 957-960
Genotypic and phenotypic analysis of 34 cases of inherited junctional epidermolysis bullosa caused by COL17A1 mutations
A.L. Hérissé,A. Charlesworth,N. Bellon,S. Leclerc-Mercier,E. Bourrat,S. Hadj-Rabia,C. Bodemer,J.P. Lacour,C. Chiaverini
doi : 10.1111/bjd.19752
British Journal of DermatologyVolume 184, Issue 5 p. 960-962
Dapsone-induced agranulocytosis: symptoms may alert more reliably than the current blood monitoring protocol
K. St Claire,S. Kaul,E.G. Caldito,O.N. Kramer,T. Griffin,J. Albrecht
doi : 10.1111/bjd.19708
British Journal of DermatologyVolume 184, Issue 5 p. 962-963
Guidelines for the management of hidradenitis suppurativa: recommendations supported by the Centre of Evidence of the French Society of Dermatology
A. Bertolotti,E. Sbidian,O. Join-Lambert,I. Bourgault-Villada,M. Moyal-Barracco,P. Perrot,N. Jouan,Y. Yordanov,S. Sidorkiewicz,K. Chazelas,M.-F. Bru-Daprés,E. Caumes,J.-F. Sei,for the HS working group,O. Chosidow,M. Beylot-Barry,on behalf of the Centre of Evidence of the French Society of Dermatology
doi : 10.1111/bjd.19710
British Journal of DermatologyVolume 184, Issue 5 p. 963-965
Successful treatment of recalcitrant hidradenitis suppurativa with risankizumab after failure of anti-tumour necrosis factor alpha
E. Marques,P. Arenberger,A. Smetanov?,S. Gkalpakiotis,D. Zimov?,M. Arenbergerov?
doi : 10.1111/bjd.19716
British Journal of DermatologyVolume 184, Issue 5 p. 966-967
A germline mutation in the platelet-derived growth factor receptor beta gene may be implicated in hereditary progressive mucinous histiocytosis
A. Onoufriadis,B. Boulouadnine,G. Dachy,T. Higashino,H.Y. Huang,C.K. Hsu,M.A. Simpson,K. Bork,J.B. Demoulin,J.A. McGrath
doi : 10.1111/bjd.19717
British Journal of DermatologyVolume 184, Issue 5 p. 967-970
COVID-19-related dermatosis in November 2019: could this case be Italy’s patient zero?
R. Gianotti,M. Barberis,G. Fellegara,C. Galv?n-Casas,E. Gianotti
doi : 10.1111/bjd.19804
British Journal of DermatologyVolume 184, Issue 5 p. 970-971
Words matter: a randomized controlled study evaluating the impact of decision-framing on treatment preferences in adults with psoriasis and psoriatic arthritis
A.A. Kassardjian,V.S. Chat,L. Archuleta,J. Hekmatjah,T.J. Sierro,C. Read,A.Y. Chen,I. Singh,A.W. Armstrong
doi : 10.1111/bjd.19746
British Journal of DermatologyVolume 184, Issue 5 p. 971-973
Interleukin-18 is a sensitive marker of flare initiation in Adamantiades–Behçet disease
C.C. Zouboulis,A. Altenburg
doi : 10.1111/bjd.19745
British Journal of DermatologyVolume 184, Issue 5 p. 973-975
Establishing cut-off values for mild, moderate and severe disease in patients with pemphigus using the Pemphigus Disease Area Index
R.L. Krain,C.E. Bax,S. Chakka,S. Ahmed,R. Feng,A.S. Payne,V.P. Werth
doi : 10.1111/bjd.19718
British Journal of DermatologyVolume 184, Issue 5 p. 975-977
Low-dose oral minoxidil improves global hair density and length in children with loose anagen hair syndrome
R. Jerjen,W.-L. Koh,R. Sinclair,B. Bhoyrul
doi : 10.1111/bjd.19756
British Journal of DermatologyVolume 184, Issue 5 p. 977-978
Real-world experience of using mogamulizumab in relapsed/refractory mycosis fungoides/Sézary syndrome
K. Molloy,C. Vico,P. L. Ortiz-Romero,J. J. Scarisbrick
doi : 10.1111/bjd.19720
British Journal of DermatologyVolume 184, Issue 5 p. 978-981
Online decision aid for patients with psoriasis
G.E. van der Kraaij,A.M. van Huizen,E.M. Baerveldt,M. Boshuizen,D. Determann,I. van Ee,M. Hageman,W. de Kort,G. Tafuni,P.M.G. Smeets,Ph.I. Spuls
doi : 10.1111/bjd.19761
British Journal of DermatologyVolume 184, Issue 5 p. 981-983
Response to Tembhre et al.: ‘Enhanced expression of angiotensin-converting enzyme 2 in psoriatic skin and its upregulation in keratinocytes by interferon-?: implication of inflammatory milieu in skin tropism of SARS-CoV-2’
J.R. Gehlhausen,C.J. Ko,W. Damsky
doi : 10.1111/bjd.19714
British Journal of DermatologyVolume 184, Issue 5 p. 984-984
Dear Editor, We recently read with great interest the research letter by Tembhre and colleagues1 in which the authors describe that while expression patterns of angiotensin-converting enzyme 2 (ACE2) and other cofactors of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) have been characterized in the skin during homeostatic conditions, they have not been examined in the state of pathogenic inflammation. To follow up on the hypothesis that ACE2 is an interferon-stimulated gene (ISG), the authors evaluated psoriasis skin biopsies and performed in vitro experiments with cultured keratinocytes. The rationale for the experiments is reasonable, though we feel some additional commentary is warranted.
Obituary: Professor Malcolm Greaves, 1933–2021
A. Kobza Black
doi : 10.1111/bjd.19864
British Journal of DermatologyVolume 184, Issue 5 p. 985-986
no abstract
Successful treatment of refractory extensive pityriasis rubra pilaris with risankizumab
J. Ricar,P. Cetkovska
doi : 10.1111/bjd.19681
British Journal of DermatologyVolume 184, Issue 5 p. e148-e148
no abstract
Silicone granuloma at a venepuncture site
M. Ota
doi : 10.1111/bjd.19695
British Journal of DermatologyVolume 184, Issue 5 p. e149-e149
no abstract
16th Medical Dermatology Meeting, Virtual Abstracts, 14 January 2021
doi : 10.1111/bjd.19933
British Journal of DermatologyVolume 184, Issue 5 p. e150-e165
no abstract
Secukinumab 2-weekly vs. 4-weekly dosing in plaque-type psoriasis
doi : 10.1111/bjd.19901
British Journal of DermatologyVolume 184, Issue 5 p. e166-e166
Psoriasis is a disease that causes scaly patches of skin that can cover large areas of the body including the scalp, hands and feet, and people’s nails can be affected too. It can greatly reduce quality of life for those that are affected.
Computer machine-learning tools help identify how different anti-inflammatory treatments affect skin cells
doi : 10.1111/bjd.19902
British Journal of DermatologyVolume 184, Issue 5 p. e167-e167
Eczema and psoriasis affect up to one in 10 adults and as many as one in five children. These conditions are caused by skin cells not communicating properly, leading to a state known as inflammation, which changes how the skin works. Following recent research advances we have a good understanding of the type of inflammation involved in eczema and psoriasis, and this has led to the development and use of targeted therapies. However, we do not fully understand how targeted and less targeted treatments affect different skin cell types, and the communication between them.
An investigation into components of the surface layer of the skin that help protect against the spread of skin cancer
doi : 10.1111/bjd.19903
British Journal of DermatologyVolume 184, Issue 5 p. e168-e168
Cutaneous squamous cell carcinoma (cSCC) is the second most common type of skin cancer in Western countries. Arising in the surface layer (epidermis) it has the ability to penetrate into the deeper layer (dermis), to spread to others parts of the body, and occasionally kill the patient. Natural protections against such spread include the body’s immune reaction and also the basement membrane, a structure which separates the epidermis from the dermis.
Using patient and melanoma tissue information to predict the risk of cancer spreading to the lymph nodes (CP-GEP tool)
doi : 10.1111/bjd.19904
British Journal of DermatologyVolume 184, Issue 5 p. e169-e169
Melanoma is the most deadly type of skin cancer that develops in skin pigment cells. It affects about 132,000 people worldwide each year. The prognosis (predicting the outcome) in newly diagnosed patients strongly depends on the presence of spread from the skin into regional lymph nodes (glands) or even further into other parts of the body, such as the lungs and bones.
How can we best use scoring scales that can be completed in clinic for assessing improvements in the severity of eczema?
doi : 10.1111/bjd.19905
British Journal of DermatologyVolume 184, Issue 5 p. e170-e170
Atopic eczema, like other forms of eczema varies, in severity. This can be expressed by, for instance, how itchy the rash is or how much of the body is covered with the rash. In order to measure the severity of eczema in patients attending a clinic or participating in clinical trials, different scoring scales, which can be completed by the doctor or patient have been devised. These are useful as they provide objective measures through which improvements or worsening of the eczema can be judged and, in turn, this is helpful in adapting treatments to the benefit of patients. The most frequently used of these scoring systems, which are questionnaires, are the Eczema Area and Severity Index (EASI) and Scoring Atopic Dermatitis (SCORAD) or the Objective SCORAD. However, their value in detecting the smallest changes that might be used to measure improvements in a patient’s illness known as the ‘minimum important change’ has never been assessed previously. Practically this means finding the level of decrease in each severity score that is associated with a real or significant improvement in eczema.
How TKFC gene abnormalities might result in loose hair
doi : 10.1111/bjd.19906
British Journal of DermatologyVolume 184, Issue 5 p. e171-e171
There are lots of reasons why people lose some of their hair. Sometimes the causes can include inherited changes in a person’s own DNA (genetic material). In our study, we examined the DNA of a 3-year-old girl who had very loose hairs; just tugging the hair gently resulted in a lot of it falling out.
How good is the new HASI-R tool at measuring hidradenitis suppurativa severity?
doi : 10.1111/bjd.19907
British Journal of DermatologyVolume 184, Issue 5 p. e172-e172
Hidradenitis suppurativa (HS) is a condition that causes painful nodules, abscess and tunnels, typically in body folds such as the armpits and groin. It effects one out of 100–1000 people. It is important to be able to measure HS severity in clinical trials so we can understand how well new treatments work.
Results of the HI-Light Vitiligo Trial: a clinical trial of corticosteroid ointment and home-based narrowband ultraviolet light for vitiligo
doi : 10.1111/bjd.19908
British Journal of DermatologyVolume 184, Issue 5 p. e173-e173
Vitiligo is a skin condition that causes loss of pigment (white patches) on the skin. It affects 1–2% of the world’s population. The HI-Light Vitiligo Trial aimed to find out whether treating vitiligo at home with a particular type of ultraviolet light (NB-UVB), either by itself or with a steroid ointment, is better than treatment using a steroid ointment on its own.
Do treatments for vitiligo offer value for money?
doi : 10.1111/bjd.19909
British Journal of DermatologyVolume 184, Issue 5 p. e174-e174
Vitiligo is a relatively common skin condition that causes white patches on the skin. Very little is known about the value for money of vitiligo treatments for the National Health Service (NHS) and patients. The HI-Light Vitiligo Trial was conducted in the UK and included 398 adults and 119 children with vitiligo. These volunteers were randomly allocated to one of three treatment groups: (i) corticosteroid ointment used every other week – normal care; (ii) handheld narrowband ultraviolet B (NB-UVB) light device used on alternate days; or (iii) both treatments used together. After 9 months of treatment, the success of the treatment and costs were compared with normal care.
Atopic eczema and the risk of obesity
doi : 10.1111/bjd.19910
British Journal of DermatologyVolume 184, Issue 5 p. e175-e175
Atopic eczema (also known as eczema) is a common skin problem, occurring in up to 10% of adults. It causes dry and itchy skin. Eczema can have a large impact on quality of life. For example, people with eczema may be less likely to exercise (as sweating can make eczema worse) and may have disturbed sleep, which can increase bodyweight. Being overweight or obese is very common (affecting 39% of adults worldwide) and is also linked to inflammation in the body.
What microbes live in the human hair follicle and what is their role?
doi : 10.1111/bjd.19911
British Journal of DermatologyVolume 184, Issue 5 p. e176-e176
The hair follicle is less acidic, moister and more protected from ultraviolet radiation when compared with the rest of the skin. As a consequence, the microorganisms that live within hair follicles (the hair follicle microbiome) differ from those living on the surface of the skin. However, these have not been as comprehensively studied. In this review, the authors, from Germany, the UK and the USA summarize our understanding regarding the influence of the hair follicle microbiome in health and disease.
Understanding itch in epidermolysis bullosa (EB)
doi : 10.1111/bjd.19912
British Journal of DermatologyVolume 184, Issue 5 p. e177-e177
Epidermolysis bullosa (EB) is a group of genetic disorders in which the skin is extremely fragile. People with severe types suffer from widespread blisters and sores, sometimes also involving internal membranes. As well as pain, patients experience severe itch, particularly in healing wounds and surrounding skin. Scratching causes more itchy wounds leading to a vicious cycle of itching and scratching. This paper from international EB experts reviews what we know about EB itch.
Impacts of itch in children
doi : 10.1111/bjd.19913
British Journal of DermatologyVolume 184, Issue 5 p. e178-e178
Many children have itchy skin diseases that affect the quality of their lives. However, there have been few studies that address the features of itch and how it impacts everyday life. To achieve our goal to identify themes about how children experience itch and its impacts, we interviewed 15 children with itch. We confirmed the importance of how severe itch is, and found that children also described how itch feels, how long it lasts, and how often it occurs.
Diagnosis of COVID-19 using skin rashes
doi : 10.1111/bjd.19914
British Journal of DermatologyVolume 184, Issue 5 p. e179-e179
Several studies have observed that patients hospitalized with COVID-19 experienced unusual skin rashes, such as urticaria (‘nettle rash’), chickenpox-type rash, and reddish and purplish bumps on the fingers or toes.
?????????????? 2 ??????? 4 ??????????
doi : 10.1111/bjd.19915
British Journal of DermatologyVolume 184, Issue 5 p. e180-e180
?????????????????, ?????????????, ??????????, ????????????????????????
????????????????????????????????
doi : 10.1111/bjd.19916
British Journal of DermatologyVolume 184, Issue 5 p. e181-e181
???????????????????????????????????????????????????, ????????, ??????????????????, ?????????????????????, ?????????????????, ??????????????????????????, ????????????????
????????????, ????????????
doi : 10.1111/bjd.19917
British Journal of DermatologyVolume 184, Issue 5 p. e182-e182
??????? (cSCC) ?????????????????????? (??) , ?????? (??) , ?????????, ?????????????????????? (?????????????) ?????????????
?????????????????????????? (CP-GEP ??)
doi : 10.1111/bjd.19918
British Journal of DermatologyVolume 184, Issue 5 p. e183-e183
??????????????, ????????????????? 132,000 ????????????????? (????) ?????????????????????? (??) , ?????????????? (??????) ????
??????????????????????????????????????
doi : 10.1111/bjd.19919
British Journal of DermatologyVolume 184, Issue 5 p. e184-e184
???????????????, ?????????????, ??????????????????????????, ?????????????????????????????, ????????????, ????????????????????, ??????????, ??????, ????????????????, ???, ???????????, ??????????????????????, ???????????? (EASI) ???????? (SCORAD) ??? SCORAD???, ????????????????????? (?“??????”) ??, ????????????????, ???????????????????????????????????
TKFC ????????????
doi : 10.1111/bjd.19920
British Journal of DermatologyVolume 184, Issue 5 p. e185-e185
??????????????????????? DNA (????) ?????????????, ?????????????? 3 ???? DNA; ???????????????????
?? HASI-R ?????????????????????????
doi : 10.1111/bjd.19921
British Journal of DermatologyVolume 184, Issue 5 p. e186-e186
?????? (HS) ???????????????????, ???????????????????? 100 ? 1000 ??????????????????????? HS ??????????, ?????????????????????
HI-Light ???????: ?????????????????????????????
doi : 10.1111/bjd.19922
British Journal of DermatologyVolume 184, Issue 5 p. e187-e187
?????????????? (??) ???????? 1–2% ???????HI-Light ???????????????????????? (NB-UVB) ??????, ??????????????????, ??????????????????
??????????????????
doi : 10.1111/bjd.19923
British Journal of DermatologyVolume 184, Issue 5 p. e188-e188
???????????????, ???????????????????????? (NHS) ?????, ?????????????, ?????????????? HI-Light ???????? 398 ????????? 119 ??????????????????????????????: (i) ?????????????——??????; (ii) ???????? B (NB-UVB) ????, ????; ? (iii) ?????????????? 9 ???, ???????????????????
???????????
doi : 10.1111/bjd.19924
British Journal of DermatologyVolume 184, Issue 5 p. e189-e189
????? (?????) ??????????, ?????????? 10%????????????????????????????????, ????????????? (??????????) , ???????, ??????????????? (???? 39% ????) , ?????????
???????????????????????
doi : 10.1111/bjd.19925
British Journal of DermatologyVolume 184, Issue 5 p. e190-e190
??????????, ???????????, ?????????????, ?????????? (??????) ?????????????????, ??????????????????, ?????????????????????????????????????
???????? (EB) ??????
doi : 10.1111/bjd.19927
British Journal of DermatologyVolume 184, Issue 5 p. e191-e191
??????? (EB) ????????, ??????, ??????????????????????????, ??????????????, ??????????, ????????????????????????????, ????????????????????? EB ??????????? EB ??????
????????
doi : 10.1111/bjd.19928
British Journal of DermatologyVolume 184, Issue 5 p. e192-e192
?????????????, ????????????, ?????????????????????????????????, ???????????????????, ????? 15 ????????????????????????, ????, ?????????????????????????
??????????
doi : 10.1111/bjd.19929
British Journal of DermatologyVolume 184, Issue 5 p. e193-e193
??????, ????? (COVID-19) ??????????????, ???? (“??”)??????, ???????????????????
